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Background: Triple negative breast cancers (TNBC) have poor prognoses despite 
aggressive treatment with cytotoxic chemotherapy. Cancer associated fibroblasts (CAFs) 
are prominent in tumour stroma. Our hypothesis was that CAFs modulate chemotherapy 
sensitivity.  
 
Methods: TNBC cells and breast fibroblasts were cultured; survival after chemotherapeutics 
was assessed using luciferase or clonogenic assays. Signaling was investigated using 
transcriptomics, reporters, recombinant proteins and blocking antibodies. Clinical relevance 
was investigated using immunohistochemistry.   
 
Results: Breast CAFs dose-dependently protected TNBC cell lines MDA-MB-231 and MDA-
MB-157, but not MDA-MB-468s, from chemotherapy. CAF-induced protection was 
associated with interferon (IFN) activation. CAFs were induced to express IFNβ1 by 
chemotherapy and TNBC co-culture, leading to paracrine activation in cancer cells. 
Recombinant IFNs were sufficient to protect MDA-MB-231 and MDA-MB-157 but not MDA-
MB-468 cells. In TNBC patients, IFNβ1 expression in CAFs correlated with cancer cell 
expression of MX1, a marker of activated IFN signaling. High expression of IFNβ1 (CAFs) or 
MX1 (tumour cells) correlated with reduced survival after chemotherapy, especially in 
claudin-low tumours (which MDA-MB-231 and MDA-MB-157 cells represent). Antibodies that 
block IFN receptors reduced CAF-dependent chemoprotection.  
 
Conclusions: CAF-induced activation of IFN signaling in claudin-low TNBCs results in 






Breast cancer is the most common malignancy in women and the second most common 
overall, causing ~600,000 deaths annually worldwide1. Breast cancers are classified 
clinically into different molecular subtypes2, based mainly on expression of estrogen 
receptor, progresterone receptor, and HER2, and this classification defines suitable 
therapeutic options, including agents targeting estrogen or HER2 function. Triple negative 
breast cancers (TNBC), which make up ~15% of breast cancers, do not express these 
markers, and accordingly cytotoxic chemotherapy is the only appropriate systemic therapy2. 
However, TNBC outcomes are relatively poor despite this aggressive treatment3.   
 
The tumour microenvironment has potent and complex influences on breast cancer 
behaviour4. Cancer associated fibroblasts (CAFs) are a major cellular component of breast 
tumour microenvironment5, and have been shown to promote cancer proliferation, invasion 
and metastases through paracrine signaling pathways, such as secretion of VEGF, FGF2, 
TGFβ, CXCL12, and IL6, as well as indirectly through modifications to extra-cellular matrix6. 
Accordingly, the presence of CAFs is significantly associated with poor outcomes from 
breast cancer generally7, and in TNBC specifically8. An alternative explanation for this 
correlation is that CAFs directly influence therapy response, potentially inducing therapy 
resistance9. The predominant model that links CAFs to therapy response involves CAF-
modified extra-cellular matrix6,10 that changes physical tissue properties11,12 and therefore 
drug permeability6. Direct paracrine influences of CAFs on therapeutic response, particularly 
to cytotoxic chemotherapy in TNBCs, have received relatively little study. Interestingly, some 
CAF-secreted paracrine mediators of chemotherapy response in TNBC have been identified, 
for example FGF5 and CXCL12 have been shown to promote resistance to docetaxel in 
mouse-models10 and to paclitaxel in 3D-culture models13 respectively. Identification of 
specific examples of molecular cross-talk between CAFs and TNBC cancer cells, such as 
these, presents opportunities for inhibition of the interactions and therefore chemo-
sensitisation to improve TNBC outcomes10. Our hypothesis was that CAFs directly modulate 
responses of TNBC cells to cytotoxic chemotherapy, and therefore that the differential 
responses of tumours may be driven in part by impact of variable CAF activity. We aimed to 
identify molecules responsible for such cellular cross-talk and to determine whether the 






Ethics and patients 
Ethical permissions for use of fibroblasts from breast cancer resections, and of archival 
tissue and associated clinico-pathological data from patients was granted by Leeds (East) 
REC (references: 09/H1326/108, 06/Q1206/180). Patients were diagnosed and treated 
within Leeds Teaching Hospitals NHS Trust; they were recruited and informed consent was 
taken in line with these permissions. For tissue microarrays, patients were diagnosed 
between 01/01/2008 and 30/03/2013; inclusion criteria were clinically defined as ER, PR, 
HER2 negative, lack of neoadjuvant therapies, availability of suitable archival (FFPE) tumour 
tissue, and availability of at least 2 months follow up.  
 
Reagents 
Epirubicin hydrochloride (Sigma; St Louis, USA); recombinant IFNα and IFNγ (Peprotech; 
Rocky Hill, USA); mouse anti-human IFN Type I R2 antibody (#MMHAR-2; PBL Assay 
Science; Piscataway, USA); goat anti-human IFN Type II R1 antibody, mouse IgG2A control, 
goat IgG control (#AF673, #MAB00, #AB-108-C 3; R&D Systems; Minneapolis, USA); rabbit 
anti-IFNβ1 and anti-claudin-3 antibodies (#PA5-20390, #PA5-16867; ThermoFisher; 
Waltham, USA); rabbit monoclonal MX1 antibody (#D3W7I; CST; MA, USA). 
 
Tissue culture 
MDA-MB-231, MDA-MB-468 and MDA-MB-157 cells were purchased from ATCC 
(Manassas, USA) and MDA-MB-231-luc from Cell Biolabs (San Diego, USA). Cells that 
stably express GFP and firefly luciferase (MDA-MB-231-GFP/luc), or GFP (MDA-MB-468-
GFP) were developed by transduction with lentiviruses14. Breast normal fibroblasts (NFs) or 
CAFs were extracted from breast cancer resections from >1cm outside tumour margins, or 
from inside tumour masses respectively. Fibroblasts were used as primary lines (passage 5-
10), or immortalised by viral transduction to over-express hTERT15. CAF-GFP cells were 
developed by lentiviral transduction16. Cells were cultured (370C) in media from 
Thermofisher (Waltham, USA) with 10% FCS (Sigma; St Louis, USA) and 1% 
penicillin/streptomycin (final concentrations 100 U/ml and 100μg/ml). MDA-MB-231, MDA-
MB-468 and immortalised fibroblasts were cultured in DMEM. Primary fibroblasts were 
cultured in DMEM-F12 and 5μg/ml Fungizone (Sigma; St Louis, USA). MDA-MB-157 cells 
were cultured in Leibovitz L-15. Cells were cultured in 5% CO2/air incubators, except for 
MDA-MB-157 (sealed flasks in 100% air). Cells were transfected in OptiMEM without serum 
using Lipofectamine-2000 (Thermofisher; Waltham, USA). ISRE/GAS reporter plasmids and 
renilla plasmid (pRL-TK) were gifts from Andrew Macdonald (Leeds, UK)17.  
 
Fluorescence-Activated Cell Sorting (FACS)  
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FACS was performed on cells from co-cultures or from matched mono-cultures to allow 
separate assessment of epithelial and fibroblast components by either colony forming 
assays or expression analyses. Cells were removed from culture dishes using trypsin/EDTA 
(Thermofisher; Waltham, USA) and resuspended in RPMI phenol red free media 
(Thermofisher; Waltham, USA). An Influx 6-way cell sorter (BDBiosciences; San Jose, USA) 
was used to identify GFP positive cells (488nm laser), gating on live cells on FSC/SSC. 
Typically, ~100,000 single cells of either GFP positive, GFP negative or both separately 
were collected into ice-cold RPMI phenol red free media. Representative flow plots showing 
three different co-cultures (MDA-MB-231-GFP/luc and CAF; MDA-MB-468-GFP and CAF; 
MDA-MB-157 and CAF-GFP) are shown (Fig S1). 
 
Luciferase assays 
Luciferase assays (survival assays - firefly only; reporter assays - dual) were performed 
using Promega (Madison, USA) reagents and were quantified by plate reader (Mithras-
LB940, Berthold; Bad Wildbad, Germany). For survival assays, epirubicin-treated readings 
were normalised to untreated cultures of the same fibroblast-epithelial proportions to 
determine relative survival excluding differences in epithelial cell numbers from the differing 
proportions. For reporter assays, MDA-MB-231 cells were reverse transfected with ISRE or 
GAS reporters (firefly) and pRL-TK control (renilla) for 18h, and were then re-plated in 
culture/co-culture with varying proportions of CAFs. Firefly activity was normalised to renilla.  
 
Colony forming (clonogenic) assays 
Mono-/co-cultures were established and treated with drugs/controls as described in figure 
legends. To determine survival in mono-culture experiments (for example, recombinant IFN 
treatments), cells were re-suspended in fresh medium lacking drugs or IFNs and re-plated in 
technical duplicate 10cm dishes at 500 cells per plate. Plates were incubated for 14 days 
undisturbed. Cells were then fixed/stained using Crystal Violet (Sigma; St Louis, USA) in 
50% methanol/20% ethanol. Isolated colonies (>40 cells) were counted manually. For 
experiments involving co-culture, all cultures (including 0% fibroblast/100% epithelial 
cultures) were sorted to isolate epithelial cells, which were then re-plated and assessed as 
above. Reproducibility of colony counts was confirmed: plates representing a range of 
different colony numbers were counted by two independent scorers; counts were compared; 
R2 correlation coefficient was 0.949, indicating near perfect agreement.  
 
RNA analyses 
For genome-wide transcriptome analyses, 900,000 MDA-MB-231-GFP/luc cells were sorted 
and RNA was prepared (ReliaPrep RNA minipreps; Promega; Madison, USA). Affymetrix 
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Clariom D microarray (Santa Clara, USA) analyses were performed by Paul Heath (Sheffield 
University, UK). Affymetrix transcriptome analysis console v3.0 was used to identify 
significantly differentially expressed genes (fold changes >+/-2, ANOVA p<0.05). Genes 
identified were analysed in ToppGene (https://toppgene.cchmc.org)18 using ToppFun. For 
qPCR of mRNAs, the GoTaq 2-Step RT-qPCR system was used with random primers and 
GoScript RT (Promega; Madison, USA) following the manufacturer’s protocol. qPCR was 
performed with GoTaq qPCR master mix and CXR reference dye in technical duplicates or 
triplicates using QuantStudio5 (ThermoFisher; Waltham, USA) with SYBR settings. Primers 
were supplied by IDT (Coralville, USA): OAS1 (#74007036), MX1 (#74007039), IFNA2 
(#74849839), IFNB1 (#74849836), IFNG (#74849833), ACTB (#74007033). For qPCR of 
miRNAs, TaqMan miRNA assays were used following the manufacturer’s protocols 
(ThermoFisher; Waltham, USA). qPCR was performed in technical triplicates using 
QuantStudio5 with TaqMan settings. Assays were supplied by ThermoFisher (Waltham, 
USA): miR-155-5p (#4427975), RNU48 (#4427975) Expression was determined relative to 
ACTB (mRNA) or RNU48 (miRNA) using δδct19. 
 
Tissue microarrays (TMAs) and immunohistochemistry (IHC) 
TMAs were constructed as previously20. In brief, suitable tissue areas (tumour with stroma, 
avoiding poorly cellular areas, necrosis, sclerosis) were identified on haematoxylin/eosin 
stained slides by histopathologist LMW and 3 separate 0.6mm cores of tumour tissue were 
taken from resection blocks and inserted into grids in recipient wax blocks. Clinico-
pathological data were collected (Table S1); disease free survival was defined as time from 
diagnosis with primary cancer to diagnosis of recurrence, or for those without an event, to 
last disease free follow up. IHC was performed broadly as previously21. In brief, 5μm 
sections were taken onto SuperFrost plus slides (Menzel-Glaser; Braunschweig, Germany). 
Sections were dewaxed with xylene, rehydrated with absolute ethanol, and washed in 
running tap water. Antigens were heat retrieved in 10mM citric acid buffer (pH 6.0) using a 
900W microwave (10min, high power). Slides were treated with 0.3% hydrogen peroxide 
(Thermo Fisher; Waltham, USA) followed by washes in Tris-Buffered Saline (TBS) and 
incubation in antibody diluent (ThermoFisher; Waltham, USA). Antibodies were diluted in 
antibody diluent at 1:800 (IFNβ1), 1:500 (claudin-3) or 1:50 (MX1) and were incubated on 
slides overnight (40C). Antibody diluent only was used for no primary controls. Slides were 
washed with TBS-T (0.1% Tween-20; Sigma; St Louis, USA) and TBS. SignalStain Boost 
IHC detection Reagent (HRP) and DAB substrate (Cell Signalling Technology; MA, USA) 
were used according to the manufacturer’s protocols. Slides were counterstained with 
Mayer’s Haematoxylin, followed by washing in running tap water, Scott’s water and again in 
running tap water. Slides were mounted under coverslips in DPX (Fluka; Gillingham, UK). 
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Stained sections were digitally scanned using ScanScopeXT (20x) and manually scored 
using Webscope (Aperio; Vista, CA, USA) with protocols developed by AMH (consultant 
breast histopathologist). For IFNβ1, intensity of fibroblast staining was scored as 1 (weak), 2 
(moderate) or 3 (strong). For MX1, tumour cell cytoplasmic intensity was scored as 0 
(negative), 1 (weak), 2 (moderate) or 3 (strong). For claudin-3, staining of tumour cell 
cytoplasm/membrane was scored as negative or positive. For each antibody, only intensity 
was scored since proportions of cells staining at these intensities were consistently the vast 
majority of cells, therefore proportion was not informative. All cores were scored by SJJ, with 
10% scored by a second independent scorer (AMH) to allow for statistical analysis of scoring 
reproducibility. Inter-scorer concordance was determined using Cohen’s Kappa statistics: 
0.725 (MX1), 0.672 (IFNβ1) and 1 (claudin-3), indicating near perfect, excellent or perfect 
agreement. For MX1 and IFNβ1, scores for individual cases were means of the core scores 
for that case, and expression was dichotomized into high and low groups using ROC 
analyses22. For claudin-3, cores for each case were consistently positive or negative, 
therefore dichotomization was positive in all or negative in all.  
 
Statistics 
Data were analysed in Prism (v8) (GraphPad; San Diego, USA), except for IHC correlations 





Breast CAFs, but not NFs, consistently protect MDA-MB-231 cells from chemotherapy 
Our first aim was to determine whether breast normal fibroblasts (NFs) or CAFs were able to 
influence sensitivity of TNBC cells to cytotoxic chemotherapy. Initially, we used a short-term 
co-culture survival assay with luciferase-expressing variants of the TNBC cell line, MDA-MB-
231. These were cultured alone (0% fibroblasts) or were co-cultured with either immortalised 
breast NFs or CAFs in proportions ranging 8% to 55% fibroblasts. The same total cell 
number was seeded in each case to achieve comparable overall confluency. Cultures were 
treated for 24h with different doses of the anthracycline epirubicin, which is typically used in 
breast cancer chemotherapy, or with vehicle control; doses approximated to EC50, EC20 
and EC10. Relative epithelial cell survival was assessed using luciferase assays (Fig 1A). 
As expected, epirubicin reduced epithelial survival dose-dependently (compare y-axis 
positions for different drug doses with 0% fibroblast cultures). The presence of CAFs 
significantly protected epithelial cells from chemotherapy at the lowest dose of drug 
(p=0.002) and showed trends for similar protection at both higher doses (p=0.057 and 
p=0.058), with increasing proportions of CAFs giving increasing protection. Notably, 55% 
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CAFs provided complete protection from the lowest epirubicin dose. NFs, however, showed 
no significant protection at any dose.  
 
Next, we extended this using an alternative end-point assay, clonogenic survival assays. 
These assays are more sensitive to lesser degrees of chemotherapy-induced damage, as 
for cells to count as ‘having survived’ they must be capable of repeated cell divisions. As 
before, we seeded cultures of TNBC cells either alone or with increasing proportions of 
breast NFs or CAFs. We used MDA-MB-231 cells, or a second TNBC line, MDA-MB-468, 
both of which had been transduced to over-express GFP. Cultures were treated with 
epirubicin or vehicle control for 24h. Epithelial cells were then separated from fibroblasts by 
cell sorting on GFP fluorescence, and were re-plated to assess clonogenic potential. 
Importantly, cultures without fibroblasts were also sorted to allow proper comparison with 
cells from co-cultures. Data are expressed both as numbers of colonies (Fig 1B, left), and 
relative survival after epirubicin (colony numbers after epirubicin treatment relative to 
matched untreated cultures; Fig 1B, right). First, it is worth highlighting an unexpected 
observation in the colony number data in the absence of epirubicin. Although not significant 
(p=0.087), clonogenicity of MDA-MB-231 cells increased after co-culture with increasing 
proportions of CAFs, while NFs significantly decreased MDA-MB-231 clonogenicity 
(p=0.038). CAFs did not confer this increased clonogenicity on MDA-MB-468 cells, although 
NFs significantly decreased clonogenicity (p=0.04). We concluded that fibroblasts influenced 
epithelial clonogenicity in a manner unrelated to chemotherapy response. Next, focusing on 
chemotherapy responses, epirubicin reduced clonogenic survival by ~50% in both MDA-MB-
231 and MDA-MB-468 cells in the absence of fibroblasts (Fig 1B, right; note y-axis position 
of open bars). CAFs, but not NFs, significantly protected MDA-MB-231s from epirubicin in a 
proportion-dependent manner (p=0.027), with the greatest proportion of CAFs increasing 
survival to 83% compared to <50% without CAFs. However, CAFs did not protect MDA-MB-
468 cells. Moreover, we repeated this experiment with MDA-MB-231 cells and a matched 
pair of primary breast NFs or CAFs cultured from a triple negative cancer mastectomy 
specimen (Fig 1C). We again found that CAFs, but not NFs, provided dramatic protection 
from chemotherapy. 
 
CAF-induced chemotherapy protection is associated with up-regulation of epithelial 
IFN signaling 
Our next aim was to identify gene expression changes induced by CAFs in MDA-MB-231 
cells that could be responsible for CAF-induced chemoresistance. MDA-MB-231 cells were 
cultured on their own (0% fibroblasts) or with 20% immortalised CAFs, were treated with 
epirubicin, and epithelial cells were collected by cell sorting, exactly as previously. RNA was 
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extracted. This experiment was performed three times over separate weeks to provide 
robust biological replicates, and gene expression was profiled in the three pairs of samples. 
Supervised hierarchical clustering was performed to display differences in epithelial 
expression between the conditions (Fig 2A), demonstrating that triplicates within each group 
were similar, and that substantial differences between groups were evident. Paired ANOVA 
tests were performed to identify significant differences in gene expression of at least 2-fold; 
127 genes were significantly more highly expressed in cultures with 20% CAFs, while 57 
were more highly expressed in 0% CAF cultures. To define molecular pathways involved, all 
184 differentially expressed genes were analysed for pathway enrichment using 
ToppGene18. The most significantly over-represented pathway was interferon (IFN) 
signaling, with 12 of the 69 genes annotated as pathway components by the analysis 
platform included in our input of 184 (p=5.1x10-13). The 12 differentially expressed IFN-
related genes are listed with fold-changes in each replicate in Table S2; these included 
canonical IFN-target genes MX1 and OAS123, which were up-regulated at least 15-fold by 
CAFs in all three replicates. It was also notable that miR-155, a down-stream target of24 and 
positive-feedback regulator of IFN signaling25, was similarly up-regulated in MDA-MB-231 
cells by CAFs (18.6-fold, +/- SD 2.5), as determined by qPCR using the same input RNAs. 
Overall, these data suggest that IFN signaling was up-regulated in MDA-MB-231 cells by 
CAFs during epirubicin treatment. 
 
Next, we examined whether CAF-dependent up-regulation of IFN-related genes differed with 
or without epirubicin. Therefore, cultures of MDA-MB-231 cells with or without CAFs were 
established as before, and treated with either epirubicin or with vehicle control, and qPCR 
was used to assess relative expression of IFN-regulated genes MX1, OAS1 and miR-155 in 
epithelial cells (Fig 2B upper panels). We also assessed whether expression of these 
markers was influenced by CAFs in MDA-MB-468 cells (Fig 2B lower panels). OAS1, MX1 
and miR-155 all demonstrated dramatic CAF-induced up-regulation in MDA-MB-231s, with 
expression potentially further increased by epirubicin treatment (although the effect of 
epirubicin was not statistically significant). In contrast, MDA-MB-468 showed no CAF-
dependent induction, with only minor variation in low basal levels (note the reduced y-axis 
scale). We concluded that these two cell lines showed differential abilities to respond to 
CAF-dependent up-regulation of IFN signaling, which mirrored their abilities to receive CAF-
dependent protection from epirubicin (Fig 1).  
 
MDA-MB-231 and MDA-MB-468 can be classified as claudin-low or claudin-high 
respectively26,27. In order to test whether effects of CAFs were potentially related to claudin 
subtype, the experiment was repeated with a second claudin-low TNBC line, MDA-MB-157. 
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MDA-MB-157s were cultured alone, or with 20% CAFs, and treated with epirubicin or control 
as before. Epithelial cells were again purified by cell sorting and expression of IFN markers 
was measured by qPCR (Fig 2C). Expression in MDA-MB-157 cells was very similar to 
MDA-MB-231s, with CAF-dependent activation of all three genes. We concluded that CAFs 
were capable of up-regulating IFN signaling in both representatives of claudin-low TNBCs.  
 
IFNβ1 is up-regulated in CAFs after co-culture with MDA-MB-231 cells 
Based on these data, our next hypothesis was that CAFs secrete IFNs, stimulating 
chemoresistance in receptive cells. Therefore, we tested whether we could detect IFN 
expression using qPCR for IFNα2, IFNβ1 or IFNγ. Mono-cultures of MDA-MB-231 or CAFs, 
and co-cultures of MDA-MB-231 and CAFs were established, and were treated with 
epirubicin or vehicle control as before. Co-cultures were separated, using fluorescence 
activated cell sorting as previously, to provide purified epithelial and fibroblast samples 
derived from the co-culture, while the mono-cultures were also sorted to allow comparison. 
IFNα2 was undetectable in MDA-MB-231 cells under all conditions, while it was expressed 
at levels bordering on the limit of detection in CAFs (consequently, there is substantial 
technical variation); levels in CAFs did not appear to respond to either epirubicin treatment 
or the presence of epithelial cells (Fig S2A). Similarly, IFNγ was expressed at very low 
levels; in CAFs, levels again did not appear to respond to either epirubicin or co-culture, 
while in MDA-MB-231 cells IFNγ was at least detectable in most samples (Fig S2B). IFNβ1 
was undetectable in MDA-MB-231 cells under all conditions, and in CAFs in mono-culture 
without epirubicin (Fig 3A, left). However, CAFs were stimulated to express detectable 
IFNβ1 levels by either epirubicin or co-culture with MDA-MB-231 cells, while epirubicin 
treated co-cultures showed dramatic up-regulation in CAFs to levels more than 3 orders of 
magnitude higher than any detected expression of IFNα2 or IFNγ. Furthermore, we repeated 
this analysis of IFNβ1 using primary breast CAFs (Fig 3A, right). Co-culture with MDA-MB-
231 cells also stimulated a dramatic increase in IFNβ1 expression in primary CAFs (pCAFs), 
although epirubicin had little additional effect. We concluded that co-culture with MDA-MB-
231 cells stimulated breast CAFs to produce IFNβ1, which may act back on epithelial cells to 
up-regulate IFN signaling (see Fig 2).  
 
CAFs, but not NFs, stimulate IFN signaling in co-cultured MDA-MB-231 cells 
To confirm that this signaling cross-talk was specific to CAFs, we used IFN activity luciferase 
reporters in MDA-MB-231 co-cultured with either NFs or CAFs. MDA-MB-231s were 
transiently transfected with luciferase reporters for activity of ISREs (representing type I IFN 
signaling) or GAS elements (representing type II IFN signaling), before being placed in 
mono-culture (0% fibroblasts), or co-culture with increasing proportions of either 
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immortalised NFs or CAFs, and treated with epirubicin. Relative luciferase activities were 
determined (Fig 3B). NFs did not stimulate either reporter, whereas CAFs induced a 
proportion-dependent up-regulation of both ISRE and GAS activity of up to 30-fold. We 
concluded that CAFs stimulate IFN signaling in co-cultured MDA-MB-231 cells, but NFs lack 
this ability. 
 
Recombinant IFNs are sufficient to protect MDA-MB-231 and MDA-MB-157 cells, but 
not MDA-MB-468 cells from chemotherapy 
Our next aim was to determine whether up-regulation of IFN signaling in claudin-low TNBC 
cells was sufficient to induce chemoprotection. To test this, initially we treated MDA-MB-231 
cells with a range of doses of a type I IFN (IFNα, which signals through the same pathway 
as IFNβ1 identified above) or a type II IFN (IFNγ) and determined epirubicin sensitivity using 
clonogenic survival assays as previously (Fig 4A). Both IFNs recapitulated effects seen by 
co-culture with CAFs, in that both provided significant dose-dependent protection from 
epirubicin (p<0.001). It is interesting to note that both also appeared to increase 
clonogenicity in the absence of epirubicin (Fig 4A, left), as was seen previously with CAFs 
(Fig 1B, upper left).   
 
Next, we examined effects of recombinant IFNα or IFNγ individually, or in combination, on 
chemoresponse of MDA-MB-231, MDA-MB-157, or MDA-MB-468 cells (Fig 4B). IFNα and 
IFNγ again provided significant chemoprotection to MDA-MB-231 cells, with additive effects 
when in combination (p<0.001). Similarly, in MDA-MB-157 cells, IFNα and the combination, 
although not IFNγ alone, provided significant protection (p<0.01). However, there was no 
significant change in chemoresponse in MDA-MB-468 cells. We concluded that IFNs were 
sufficient to protect both claudin-low TNBC cell lines, and therefore IFNs were strong 
candidate mediators of CAF-dependent protection. 
 
IFNβ1 expression in CAFs and tumour cell expression of MX1 correlate with each 
other and with poor survival after chemotherapy in TNBC patients  
Next, we determined whether expression of the molecules we have implicated in 
chemoresistance correlated with survival after chemotherapy in patients. We collected 109 
TNBC resection samples, supported by clinico-pathological data including length of disease-
free survival. We constructed tissue microarrays containing triplicate cores of cancer tissue 
and assessed expression of IFNβ1 in fibroblasts and MX1 as a marker of active IFN 
signaling in tumour cells using immunohistochemistry. We also determined whether 
individual cases could be classified as claudin-low, using immunohistochemistry for claudin-
3. Representative images are shown in Fig 5A. High expression of IFNβ1 in fibroblasts was 
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weakly, but significantly, positively associated with high MX1 expression in the tumour cells 
(Spearman’s correlation r=0.210; p=0.028), suggesting that signaling between the cell types 
was active. High expression of IFNβ1 in fibroblasts, and MX1 in tumour cells were each 
significantly associated with poorer disease-free survival (by means of almost 800 days; 
p<0.02 for both; Fig 5B).  
 
The cohort was also divided into claudin-low (claudin-3 negative; n=49) and claudin-high 
(claudin-3 positive; n=60) subgroups. Interestingly, IFNβ1 expression was significantly 
different between these two groups, with claudin-low tumours expressing overall higher 
levels (mean scores 2.6 [SD 0.59] vs 2.0 [SD 0.52]; Mann–Whitney p=0.001). The 
correlation between fibroblast IFNβ1 and tumour cell MX1 was strengthened in the claudin-
low group (r=0.375; p=0.008) while it was lost in the claudin-high cohort (r=0.113; p=0.389), 
mirroring our tissue culture observations that claudin-low cancers are most receptive to 
CAF-induced IFN signaling. Similarly, correlations between survival and expression of each 
of IFNβ1 in fibroblasts and MX1 in tumour cells were maintained in claudin-low cases 
(p<0.05; Fig 5C) but lost in claudin-highs (Fig S3). We also carried out multivariate analyses 
to assess whether IFNβ1 in fibroblasts and MX1 in tumour cells provided prognostic insights 
that were independent of the standard prognostic factors lymph node status and tumour 
grade. In the whole cohort, lymph node status and fibroblast IFNβ expression were 
significant independent predictors of disease free survival (with hazard ratios of 2.24 
[p=0.007] and 2.99 [p=0.001] respectively). In the claudin-low subgroup, both these factors 
remained significant, with increased hazard ratios (3.77 [p=0.034] and 3.52 [p=0.015] 
respectively). In the claudin-high subgroup, none of the factors were significantly associated 
with outcome, although lymph node status demonstrated borderline significance (hazard 
ratio 2.52 [p=0.052]). We concluded that correlations between IFNβ1 and MX1 and survival 
in breast cancer patients exactly reflect relationships identified in vitro, with CAF-induced 
IFN activity correlating with chemoresistance and consequently poor survival, specifically 
within claudin-low cancers.    
 
IFN blocking antibodies inhibit CAF-dependent chemo-protection of cancer cells 
Having defined molecular mechanisms involved in CAF-dependent chemoprotection, we 
wished to test whether these mechanisms could be inhibited, thereby potentially allowing 
chemo-sensitisation. We selected antibodies that have previously been used for blocking 
either type I or type II IFN receptors28,29. MDA-MB-231 or MDA-MB-157 cells were again 
cultured with or without CAFs, and cultures were treated with type I or type II blocking 
antibodies, or appropriate isotype controls. Cells were then treated with epirubicin or vehicle 
control, and epithelial survival was determined (Fig 6). MDA-MB-231 cells were significantly 
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protected from epirubicin by CAFs as previously (p<0.05), and this protection was 
significantly reduced by either blocking antibody (p<0.05; Fig 6A, left); notably, CAF-
dependent protection was completely inhibited with the type I antibody. MDA-MB-157 cells 
behaved similarly, although only the type I antibody significantly inhibited protection (p<0.01; 
Fig 6A, right). Importantly, we also used qPCR to assess MX1 expression as a marker of 
IFN signaling activity (Fig 6B). We again confirmed CAF-dependent up-regulation of MX1 
(as previously in Fig 2), but also established that blocking antibodies successfully inhibited 
this up-regulation in every case in which blocking antibodies also halted CAF-dependent 
protection (p<0.05), but not in the one example where blocking antibody was ineffective 
(type II antibody, MDA-MB-157). We also repeated the experiment using primary breast 
CAFs, MDA-MB-231 cells and the type I blocking antibody, and demonstrated the same 
significant ability to block CAF-dependent protection (p<0.05; Fig 6C). We concluded that 
CAF-dependent protection of breast cancer lines required induction of IFN signaling, and, 
excitingly, that this can be inhibited in order to chemo-sensitise cancer cells. However, it 
should be noted that the data shown represent only one selected dose of epirubicin, and we 
have not assessed the formal impact of CAFs and IFN-blocking antibodies on a 





Outcomes for TNBC remain relatively poor3, and much research is aimed towards identifying 
novel therapeutic targets and agents in this breast cancer subtype30. An alternative 
approach is to use the therapies already available more effectively, a strategy that drives the 
need to understand mechanisms underpinning chemotherapy resistance better31. In this 
work, we identify a resistance mechanism that acts in a subset of TNBC using in vitro 
models, and we confirm its relevance using a patient cohort.  
 
We show that breast CAFs protect claudin-low TNBCs from chemotherapy through secretion 
of IFNβ1 leading to paracrine activation of IFN signaling in the cancer cells, as denoted by 
up-regulation of MX1. Our data tie together previous reports showing that CAFs are 
associated with poor outcomes in TNBC patients8, that breast CAFs can secrete IFNβ 
thereby activating IFN signaling and influencing behaviour of breast cancer cells in vitro32,33, 
and that expression of MX1 in breast cancer cells is significantly associated with poor 
outcomes in patients34. Critically, we define the functional impact of this signaling on cancer 
cells in terms of chemotherapy resistance (Figs 1 and 4), and indeed chemotherapy-
treatment itself contributes to induction of full paracrine activity (Figs 2 and 3; 33). This is in 
contrast to much of the literature on CAFs that defines their influence in terms of inducing 
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proliferation, invasion or metastases, and therefore poor outcomes5,6. This distinction is 
important clinically, since potential inhibition of CAF-induced chemoresistance could be 
useful therapeutically10,35, whereas potential inhibition of CAF-induced invasion/metastases 
is more problematic as these processes are thought to occur prior to breast cancer 
diagnoses. A further previous study also identified chemoresistance-associated cross-talk 
between fibroblasts and claudin-low breast cancer cells36, although there are key 
mechanistic differences with our work. Boelens et al demonstrated that immortalised lung 
fibroblasts protected both MDA-MB-231 and MDA-MB-157 cells from chemotherapy via 
activation of NOTCH3 and STAT1, a key IFN-signaling intermediate, and this was 
associated with up-regulation of IFN response genes OAS1 and MX136. However, by 
marked contrast with our work, the authors determined that cellular cross-talk was mediated 
by RNA transfer via exosomes, independently of IFN or IFN receptors. We demonstrate by 
use of IFN-blocking antibodies that this action of breast CAFs is entirely dependent on 
canonical paracrine IFN-signaling (Fig 6), and we conclude that different fibroblasts signal 
using different mechanisms. We also suggest our use of both primary and immortal breast 
fibroblasts may be most relevant. 
 
A key discussion point is how these insights could be used to improve cancer outcomes. It is 
conceivable that alternative treatments could be used for patients whose TNBC tumours 
display the characteristics identified here as associated with potential anthracycline 
resistance, namely active IFN signaling between CAFs and claudin-low tumour cells (CAF 
IFNβ expression/cancer cell MX1 expression; Fig 5). However, anthracyclines, often 
combined with taxanes, are the mainstay of TNBC chemotherapy and comprehensive 
alternatives are not available, although PARP inhibitors and immune check-point inhibitors 
show potential in some settings37. A more practicable option may be to inhibit cross-talk 
between CAFs and tumour cells in order to sensitise cancer cells to the existing 
chemotherapy agents; we present proof of this principle in Fig 6. We have used receptor-
blocking antibodies experimentally since these not only inhibit the pathway required but also 
specifically target the paracrine aspect of the signaling we wished to prove. This approach 
also has clinical potential, since a humanised type I receptor blocking antibody, Anifrolumab, 
is available and has undergone clinical investigation in lupus38. In addition, ruxolitinib is a 
small molecule inhibitor of the JAK1/2 kinases, which are IFN-signaling intermediates, that 
has already been trialled at phase 2 in combination with cytotoxic chemotherapy in 
metastatic breast cancer39. We conclude that available agents may present opportunities for 
assessment of therapeutic chemo-sensitisation in the relatively near-term. 
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The claudin-low breast cancer subtype was identified more than a decade ago40, however 
claudin expression levels are not assessed in routine breast cancer management since they 
have not been found to be useful in directing treatment choices to improve outcomes41. 
Robust clinical identification of the claudin-low phenotype would be required for therapeutic 
interventions targeting the CAF-dependent chemoresistance we describe. It remains unclear 
why claudin-high tumours fail to be protected from chemotherapy by CAFs. Our data from 
patient samples suggest that claudin-high tumours have lower CAF IFNβ1 levels, therefore, 
one explanation is less IFNβ1 to activate the pathway. However, we also show that the 
IFNβ1 present does not correlate with IFN-target gene expression in claudin-high cancer 
cells, and that the claudin-high cell line, MDA-MB-468, fails to respond to either CAFs or 
recombinant IFNs in vitro, pointing to a more profound signaling defect. MDA-MB-468 cells 
have previously been shown to activate signaling downstream of the Type II ligand IFNγ42, 
although other published data for Type I signaling, as stimulated by IFNβ1, are lacking. 
Therefore, candidate defects include variation in expression/function of the Type I receptor, 
IFNAR1, which is known to vary in breast cancer and this variation correlates with 
prognosis43, or aberrant expression of interferon regulatory factors (IRFs), which act to 
modulate the range and extent of IFN target gene activation, and are also known to be 
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Fig 1. Breast CAFs, but not NFs, protect some TNBC lines from chemotherapy. A) 
MDA-MB-231-luc cells were cultured alone (0% fibroblasts) or with increasing proportions of 
immortalised breast NFs (left panel) or CAFs (right panel). Cultures were treated with three 
different doses of epirubicin as shown, or with vehicle control for 24h. Cultures were 
incubated for a further 48h in fresh medium, before survival of MDA-MB-231 was assessed 
using luciferase assays. Data represent survival after epirubicin relative to matched vehicle 
control cultures, and are means (+/-SE) of 3 independent experimental replicates. B) MDA-
MB-231-GFP/luc (top panels) or MDA-MB-468-GFP cells (bottom panels) were cultured 
alone (0% fibroblasts) or with increasing proportions of immortalised breast NFs or CAFs. 
Cultures were treated with 10nM epirubicin or vehicle control for 24h. Epithelial cells were 
then collected by FACS and clonogenic survival was determined. Data are presented as 
colony counts (left panels) or relative survival after epirubicin (colony counts after epirubicin 
relative to matched untreated cultures; right panels). Data represent means (+/-SE) of 3 
independent experimental repeats. C) MDA-MB-231-GFP/luc cells were cultured alone (0% 
fibroblasts) or with increasing proportions of primary (p) breast NFs or CAFs cultured from a 
triple negative breast cancer resection. Cultures, cells and data were treated as for part B. 
Data represent means (+/-SD) of technical duplicates from one experimental repeat. 
Statistics: linear regression was carried out for analyses in A and B, with selected significant 
differences in the overall trend across the fibroblast proportions shown (ns, not significant). 
ANOVA tests were performed in addition; these also demonstrated that CAFs provided 
significant protection from epirubicin in MDA-MB-231 cells (p<0.01; lowest dose Fig 1A and 
Fig 1B right panel) and not in MDA-MB-468 cells. 
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Fig 2. CAFs stimulate IFN signaling in some co-cultured breast epithelial cell lines. A) 
MDA-MB-231-GFP/luc cells were cultured alone (0%) or with CAFs (20%) and were treated 
with 10nM epirubicin. Epithelial cells were then collected by FACS and RNA was prepared. 
Three separate biological repeats were performed giving three pairs of samples. Gene 
expression was assessed using Affymetrix Clariom D microarrays, and comparisons were 
made between 0% and 20% groups using hierarchical clustering. B) MDA-MB-231-GFP/luc 
or MDA-MB-468-GFP cells were cultured on their own (0%) or in combination with CAFs 
(20%), with or without 10nM epirubicin. Epithelial cells were collected by FACS and RNA 
was prepared. Relative expression of interferon response genes OAS1, MX1 and miR-155 
was determined using qPCR. C) MDA-MB-157 cells were cultured on their own (0%) or in 
combination with CAF-GFP cells (20%), with or without 10nM epirubicin. Epithelial cells were 
collected by FACS and RNA was prepared. Relative expression of interferon response 
genes OAS1, MX1 and miR-155 was determined using qPCR. B, C) Data represent the 
mean of technical triplicates (+/- SD) from one biological experiment, apart from miR-155 
analysis in MDA-MB-231 cells, which is from 3 biological experiments (+/- SE) and is 
analysed using two-tailed Mann-Whitney U tests (selected significant difference shown). 
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Fig 3. Epithelial:fibroblast cross-talk induces IFNβ1 expression in CAFs and IFN-
signaling in epithelial cells. A) MDA-MB-231-GFP/luc cells were cultured alone, breast 
CAFs were cultured alone, or co-cultures of MDA-MB-231-GFP/luc cells and CAFs were 
established (80% epithelial cells with 20% fibroblasts: “20%”). CAFs used were either 
immortalised, left, or primary, right. Cultures were treated with or without 10nM epirubicin for 
24h. All cultures were processed for cell sorting, allowing separation of CAFs and MDA-MB-
231-GFP/luc cells from the co-cultures on the basis of GFP fluorescence in the CAFs. RNA 
was extracted, and qPCR used to determine relative expression of IFNβ1. Data represent 
the mean of duplicate culture wells (+/-SD) for 1 biological experiment. ND: not detected. B) 
MDA-MB-231 cells were transfected with ISRE or GAS reporter plasmids driving firefly 
luciferase expression, and a control plasmid (pRL-TK; HSV thymidine kinase promoter 
driving renilla luciferase). Transfected MDA-MB-231 cells were then cultured on their own or 
with different proportions of immortalised NFs or CAFs for 24h with 10nM epirubicin. Dual 
luciferase assays were performed, with firelfy readings normalised to renilla readings. Data 
represent means (+/-SD) for triplicate wells, for 1 biological experiment. 
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Fig 4. Recombinant IFNs are sufficient to stimulate chemoresistance in MDA-MB-231 
and MDA-MB-157 cells. A) MDA-MB-231-GFP/luc cells were cultured with a range of doses 
of IFN𝛼 or IFN𝛾 for 24h. Cells were then treated with 10nM epirubicin, or control, and 
redosed with IFNs. Clongenic survival was determined as previously. B) MDA-MB-231-
GFP/luc, MDA-468-GFP or MDA-MB-157 cells were cultured with IFN𝛼 or IFN𝛾	(2500pg/ml 
and 1500pg/ml respectively) separately or combination or with appropriate isotype control 
antibodies for 24h. Cells were then treated with epirubicin for 24h (10nM or, for MDA-MB-
157s, 25nM). Clongenic survival was determined as previously. A) and B) Data are shown 
as either colony counts (left), or survival relative to untreated (right) and represent means 
(+/-SE) of either 3 (A) or 2 (B) independent experiments. ANOVA tests were performed and 
selected differences are shown (ns, not significant). 
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Fig 5. In primary cancers, IFNβ1 in CAFs and MX1 in cancer cells correlate with each 
other and with poor survival. TMAs of tissue from 109 TNBC resections were assembled 
and expression of IFNβ1 in fibroblasts, and MX1 and claudin-3 in tumour cells was 
determined using immunohistochemistry. A) Representative images of 
immunohistochemistry, showing tissue scored ‘3’ for IFNβ in fibroblasts (left), ‘3’ for MX1, 
and ‘positive’ for claudin-3. B) The cohort was split into groups with high or low expression of 
IFNβ1 in fibroblasts (left) or MX1 in tumour cells (right) using ROC analyses. Cumulative 
disease-free survival in the groups was compared using Kaplan-Meier analyses and log rank 
tests. C) The cohort was split into claudin-low or claudin-high groups, based on expression 




Fig 6. Blocking antibodies inhibit CAF-induced chemoprotection. A and B) MDA-MB-
231-GFP/luc (left) or MDA-MB-157 (right) cells were cultured alone, or with breast CAFs or 
CAF-GFP cells respectively. Cultures were treated with type I (1μg/ml) or type II (5μg/ml) 
interferon signaling blocking antibodies or appropriate isotype controls for 24h. Cultures 
were then treated with 10nM (MDA-MB-231 cells) or 25nM (MDA-MB-157 cells) epirubicin or 
vehicle control, and were redosed with antibodies for a further 24h. Epithelial cells were then 
collected by FACS. A) Clonogenic survival was determined. Data are presented as colony 
counts or relative survival after epirubicin (colony counts relative to untreated). B) Relative 
expression of the marker of IFN signaling activity MX1 was determined. C) MDA-MB-231-
GFP/luc cells were cultured alone, or with primary breast CAFs and were treated with 
antibodies and epirubicin/control exactly as above. Clonogenic survival was determined 
(left): data are presented as colony counts or relative survival after epirubicin (colony counts 
relative to untreated). Relative expression of the marker of IFN signaling activity MX1 was 
also determined (right). A), B) and C) Data represent means (+/-SE) of 3 independent 
experimental repeats. Two-tailed Mann-Whitney U tests were carried out and selected 
differences are shown (ns, not significant). 
